Details of the Drug Reposition

General Information of This Drug (ID: DMFU0JY)

Drug Name
TH-302   DMFU0JY
Synonyms
TH-302; evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; TH-302; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Soft tissue sarcoma DISSN8XB 2B57 Phase 2 [1]
------------------------------------------------------------------------------------
4 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Squamous cell carcinoma DISQVIFL 2B60-2D01 Phase 1 [2]
Pancreatic cancer DISJC981 2C10 Phase 1 [2]
Melanoma DIS1RRCY 2C30 Phase 1 [2]
Prostate cancer DISF190Y 2C82.0 Phase 1 [2]
------------------------------------------------------------------------------------

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8695).
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)